摘要
目的 评估达利珠单抗 (抗CD2 5单克隆抗体 )诱导治疗后的抗排斥反应疗效。方法 对 1 999年 9月～ 2 0 0 4年 4月间使用达利珠单抗的 6 2例患者进行随访和统计。所有患者均在术中血管开放前 1h应用达利珠单抗 5 0mg ,术后常规应用激素、环孢素A和霉酚酸酯。根据达利珠单抗的用量分为 1剂组、2剂组和大于 2剂组。结果 随访时间最长达 4年 9个月 ,最短 3个月。随访期间共发生急性排斥 7例 (1 1 .3%) ,最早 1例发生在术后 2个月 ,最晚为术后 1 4个月 ,平均 1 0 .3个月 ;4例经过激素冲击治疗 ,完全逆转 ,2例部分逆转 ,仅 1例发生于术后 1 0个月的排斥 ,激素冲击治疗无效 ,术后第 1 3个月移植肾失功而切除。结论 应用达利珠单抗诱导治疗 ,肾移植术后急性排斥发生率降低 ,并使急性排斥发生时间推迟 ,程度减轻 ;可以安全、有效的减少环孢素的剂量。
Objective To investigate the efficacy and safety of anti CD25 Ab (Zenapax;Daclizumab) induction therapy in 62 patients following renal transplantation. Methods Sixty-two renal transplant recipients treated with Daclizumab induction therapy were analyzed retrospectively from Sep. 1999 to May 2004. Main immunosuppressive therapy regimen consisted of steroids cyclosporine and mycophenolate mofetil in all recipients after operation. According to Daclizumab dosage, these recipients were divided into 1-dose group, 2-dose group and over 2-dose group. All patients received Daclizumab 1 h before operation.Results The patients subject to Daclizumab were followed up from 3 months to 57 months. Seven of them had acute rejection ( 11.3 %) at intervals for 10.3 months, from 2 months to 14 months. Patient who had acute rejection at 10th month after operation lost his graft at 13th month after transplantation for graft dysfunction. The incidence of acute rejection was 15.6 % among 45 patients followed up over 12 months. Conclusions Induction therapy of Daclizumab could decrease the incidence of acure rejection, delay the time of acute rejection and relieve the severity of rejection. More graft can be long-survival. We can lower the dosage of CsA effectively and safely after induction of Daclizumab.
出处
《中华器官移植杂志》
CAS
CSCD
北大核心
2004年第6期326-327,共2页
Chinese Journal of Organ Transplantation
